Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Eduardo J. Pennella"'
Autor:
Hope S. Rugo, Eduardo J. Pennella, Unmesh Gopalakrishnan, Miguel Hernandez-Bronchud, Jay Herson, Hans Friedrich Koch, Subramanian Loganathan, Sarika Deodhar, Ashwani Marwah, Alexey Manikhas, Igor Bondarenko, Joseph D. Parra, Maria Luisa T. Abesamis-Tiambeng, Charuwan Akewanlop, Ihor Vynnychenko, Virote Sriuranpong, Sirshendu Roy, Eduardo Patricio Yanez Ruiz, Abhijit Barve, Cornelius F. Waller
Publikováno v:
Breast, Vol 58, Iss , Pp 18-26 (2021)
Background: Trastuzumab-dkst is a biosimilar of trastuzumab. The phase 3 HERITAGE trial demonstrated equivalent overall response rate (ORR) with trastuzumab-dkst or originator trastuzumab at 24 weeks in patients with HER2-positive metastatic breast c
Externí odkaz:
https://doaj.org/article/398ce9856ea34116bdedd35208f23846
Autor:
Cornelius F. Waller, Maria Luisa T. Abesamis-Tiambeng, Charuwan Akewanlop, Eduardo Yanez Ruiz, Ihor Vynnychenko, Unmesh Gopalakrishnan, Abhijit Barve, Jay Herson, Ashwani Marwah, Virote Sriuranpong, Sirshendu Roy, Hope S. Rugo, Alexey Manikhas, Miguel Hernandez-Bronchud, Subramanian Loganathan, Hans Friedrich Koch, Joseph D. Parra, Sarika Deodhar, Igor Bondarenko, Eduardo J. Pennella
Publikováno v:
Breast, Vol 58, Iss, Pp 18-26 (2021)
The Breast : Official Journal of the European Society of Mastology
The Breast : Official Journal of the European Society of Mastology
Background Trastuzumab-dkst is a biosimilar of trastuzumab. The phase 3 HERITAGE trial demonstrated equivalent overall response rate (ORR) with trastuzumab-dkst or originator trastuzumab at 24 weeks in patients with HER2-positive metastatic breast ca
Autor:
Alexey Manikhas, Hans Friedrich Koch, Charuwan Akewanlop, Kakhaber Baramidze, Sirshendu Roy, Gopichand Mamillapalli, Ashwani Marwah, Virote Sriuranpong, Eduardo Yanez Ruiz, Miguel Hernandez-Bronchud, Unmesh Gopalakrishnan, Maria Luisa T. Abesamis-Tiambeng, Guzel Mukhametshina, Abhijit Barve, Joseph D. Parra, Adolfo Fuentes-Alburo, Ihor Vynnychenko, Sarika Deodhar, Gia Nemsadze, Igor Bondarenko, Eduardo J. Pennella, Cornelius F. Waller, Hope S. Rugo, Jay Herson, Subramanian Loganathan
Publikováno v:
Breast Cancer Research and Treatment
Breast cancer research and treatment, vol 188, iss 2
Breast cancer research and treatment, vol 188, iss 2
Purpose The phase 3 HERITAGE trial demonstrated that the biosimilar trastuzumab-dkst is well tolerated with similar efficacy (measured by overall response rate [ORR] and progression-free survival [PFS]) compared with originator trastuzumab combined w
Autor:
Nilanjan Sengupta, Cornelius F. Waller, Andrew D. Shaw, Charles Donnelly, Mark Liu, Parag Goyal, Rajiv Sharma, Abhijit Barve, Apinya Vutikullird, Mark Baczkowski, Eduardo J. Pennella, Tracey E. Lawrence
Publikováno v:
British Journal of Clinical Pharmacology. 84:2336-2343
Aims Trastuzumab is a humanized monoclonal antibody that binds the human epidermal growth factor receptor 2 (HER2) oncoprotein and is an effective therapy for HER2-overexpressing breast cancer. MYL-1401O is a trastuzumab biosimilar. Here, we report r
Autor:
Michael Kuo, Armin Ghobadi, Mira Pavelova, Julie Vanas, Charles Powell, Raffit Hassan, Cathy Wagner, Christina M. Annunziata, Premal H. Thaker, Eduardo J. Pennella, Claudio Dansky Ullmann
Publikováno v:
Journal of Clinical Oncology. 38:3014-3014
3014 Background: MCY-M11 is a mesothelin-targeting chimeric antigen receptor (CAR) therapy made by a non-viral, mRNA-based platform, for rapid ( < 1 day) CAR manufacturing. We are conducting a phase I dose escalation trial in ovarian cancer and malig
Autor:
Gopinath Ranganna, Leonard A. Mattano, Mudgal Kothekar, Katrin Beckmann, István Láng, Iryna Lytvyn, Yaroslav Shparyk, Cornelius F. Waller, Mark Baczkowski, Eduardo J. Pennella, Rajiv Sharma, Christopher Blakeley, Oleksandr Berzoy, Vasil Popov, Andriy Rusyn, Miguel H. Bronchud, Nataliia Voitko, Abhijit Barve
Publikováno v:
Annals of hematology. 98(5)
Pegfilgrastim is indicated for reducing the duration of neutropenia and incidence of febrile neutropenia in patients receiving cytotoxic chemotherapy. Here, safety and efficacy of MYL-1401H, a proposed pegfilgrastim biosimilar, were investigated as p
Autor:
Cornelius F. Waller, Catherine E. Micales, Gopinath Ranganna, Renger G. Tiessen, Mark Liu, Andrew D. Shaw, Rajiv Sharma, Mark Baczkowski, Eduardo J. Pennella, Mudgal Kothekar, Abhijit Barve, Tracey E. Lawrence
Publikováno v:
Journal of cancer research and clinical oncology. 144(6)
Pegfilgrastim is a long-acting granulocyte colony-stimulating factor indicated for prevention of febrile neutropenia in patients receiving myelosuppressive chemotherapy by promoting neutrophil recovery. This phase 1, randomized, double-blind, three-w
Autor:
Coleman K. Obasaju, Ramaswamy Govindan, Shi Li, Jingyi Liu, Eduardo J. Pennella, David R. Spigel, Mark A. Socinski, Edward B. Garon, Jyoti D. Patel, Mark R. Olsen, Robert C. Hermann, Susan C. Guba, Craig H. Reynolds, Philip Bonomi
Publikováno v:
Clinical Lung Cancer. 16:200-208
Introduction African Americans have a greater incidence of lung cancer than whites and have been underrepresented in clinical trials. In the PointBreak trial (pemetrexed-carboplatin-bevacizumab and maintenance pemetrexed-bevacizumab [PemCBev] vs. pac
Autor:
Guangbin Peng, Catherine Muehlenbein, D. Neil Hayes, Gebra Cuyun Carter, Coleman K. Obasaju, Anwar Hossain, Eduardo J. Pennella
Publikováno v:
Oral Oncology. 50:605-610
Summary Objectives Previous retrospective analyses show poor outcomes for African American (AA) patients with head and neck carcinoma (HNC). Such racial disparities are not well understood, and generally studies have been too small to investigate sub
Autor:
Ihor Vynnychenko, Virote Sriuranpong, Jinyu Yuan, Jay Herson, Eduardo Yanez Ruiz, Guzel Mukhametshina, Hope S. Rugo, Gia Nemsadze, Alexey Manikhas, Eduardo J. Pennella, Sirshendu Ray, Gopichand Mamillapalli, Igor Bondarenko, Kakhaber Baramidze, Charuwan Akewanlop, Mudgal Kothekar, Mark Baczkowski, Joseph D. Parra, Rajiv Sharma, Subramanian Loganathan, Miguel Hernandez-Bronchud, Cornelius F. Waller, Maria Luisa T. Abesamis-Tiambeng, Abhijit Barve
Publikováno v:
JAMA. 317(1)
Importance Treatment with the anti-ERBB2 humanized monoclonal antibody trastuzumab and chemotherapy significantly improves outcome in patients with ERBB2 (HER2)–positive metastatic breast cancer; a clinically effective biosimilar may help increase